MedTrace Logo

Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis

NCT01199887 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2013-07-29

No results posted yet for this study

Summary

This is an open label, Phase One, multicenter study, designed to evaluate the safety, tolerability, to explore the biologic effects, and to explore the clinical effects of the following doses of IW001: 0.1mg/day, 0.5 mg/day, and 1.0 mg/day, when administered once a day orally for 24 weeks in patients with IPF.

Conditions

Interventions

DRUG

IW001

IW001, 0.1 mg, 0.5 mg, 1.0 mg PO daily for 24 weeks.

Sponsors & Collaborators

  • ImmuneWorks

    lead INDUSTRY

Principal Investigators

  • Terrence Chew, MD · ImmuneWorks, Medical Consultant

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01199887 on ClinicalTrials.gov